ENZ Logo

Enzo Biochem, Inc. (ENZ) 

NYSE
Market Cap
$53.55M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
451 of 963
Rank in Industry
26 of 53

Largest Insider Buys in Sector

ENZ Stock Price History Chart

ENZ Stock Performance

About Enzo Biochem, Inc.

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Insider Activity of Enzo Biochem, Inc.

Over the last 12 months, insiders at Enzo Biochem, Inc. have bought $0 and sold $0 worth of Enzo Biochem, Inc. stock.

On average, over the past 5 years, insiders at Enzo Biochem, Inc. have bought $261,776 and sold $2.09M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $12,875 was made by Wolf James G. () on 2023‑02‑13.

List of Insider Buy and Sell Transactions, Enzo Biochem, Inc.

2023-02-13Purchase
10,000
0.0208%
$1.29$12,875+10.83%
2023-02-10Purchase
5,000
0.0103%
$1.29$6,450+9.30%
2023-01-27Purchasedirector
11,800
0.024%
$1.40$16,5200.00%
2022-11-23PurchaseChief Executive Officer
100,000
0.2052%
$1.97$197,000-24.37%
2022-11-01Purchasedirector
8,500
0.0172%
$2.14$18,225-28.57%
2022-10-31Purchasedirector
14,500
0.0299%
$2.15$31,175-27.57%
2022-07-15PurchaseChief Operating Officer
2,500
0.0052%
$2.42$6,050-9.17%
2022-07-12Purchase
12,500
0.0243%
$2.27$28,375-9.17%
2022-07-05Purchase
120,000
0.2362%
$2.20$264,000-4.78%
2022-06-15Purchase
75,000
0.1523%
$2.20$165,000-1.35%
2022-06-15PurchaseChief Executive Officer
4,600
0.0093%
$2.19$10,074-1.35%
2022-06-14PurchaseChief Financial Officer
3,500
0.0074%
$2.15$7,525+4.76%
2021-03-16Sale10 percent owner
300,000
0.706%
$4.65$1.39M-19.61%
2021-03-15Sale10 percent owner
144,768
0.4879%
$4.83$698,840+10.81%
2020-02-18Purchase10 percent owner
4,000
0.0082%
$2.20$8,800+7.14%
2020-02-14Purchase10 percent owner
6,000
0.0125%
$2.21$13,260+7.66%
2019-08-20Purchase10 percent owner
9,700
0.0202%
$3.11$30,167-16.24%
2019-08-16Purchase10 percent owner
22,800
0.0456%
$3.06$69,768-18.32%
2019-07-23Purchase10 percent owner
409,200
0.87%
$3.65$1.49M-24.93%
2019-07-22Purchase10 percent owner
9,644
0.0201%
$3.64$35,104-26.36%

Insider Historical Profitability

<0.0001%
HARBERT MANAGEMENT CORP10 percent owner
5175913
9.9072%
$1.0382<0.0001%
Radoff Bradley Louis
4194663
8.029%
$1.0330<0.0001%
Wolf James G.
4100000
7.8478%
$1.0350<0.0001%
RABBANI ELAZARChm of the Bd, CEO and Sec
1848668
3.5385%
$1.0323+1.13%
RABBANI SHAHRAM KTreasurer, Secretary
1828494
3.4999%
$1.0315<0.0001%
WEINER BARRY WPresident, CFO, Treasurer, PAO
1302111
2.4924%
$1.0313<0.0001%
Erfanian HamidChief Executive Officer
374600
0.717%
$1.0320<0.0001%
Perlysky Dovdirector
266235
0.5096%
$1.0311+0.29%
BORTZ GREGORY M.director
250870
0.4802%
$1.0301
ENGELHARDT DEANExecutive Vice President
153651
0.2941%
$1.0306
KELKER NORMAN ESenior Vice President
104583
0.2002%
$1.0304
THALENFELD BARBARA EVP, Corporate Development
60813
0.1164%
$1.0315<0.0001%
LAZAR MELVIN Fdirector
50375
0.0964%
$1.0350<0.0001%
Hanna Bruce A.director
37816
0.0724%
$1.0310+0.29%
O'Brien James MichaelEVP of Finance
28187
0.054%
$1.0302
BALEZENTIS CARL WPres., Enzo Life Sciences
25950
0.0497%
$1.0303
CLEMENS PETER J IV10 percent owner
15000
0.0287%
$1.0320+7.4%
Kent Stephen B Hdirector
9654
0.0185%
$1.0305
KRENITSKY KEVINPresident, Enzo Clinical Labs
6600
0.0126%
$1.0310<0.0001%
Bench DavidChief Financial Officer
6000
0.0115%
$1.0310+4.76%
Cannon KaraChief Operating Officer
2500
0.0048%
$1.0310<0.0001%
KASTEN BERNARD Ldirector
0
0%
$1.0305
WARSHAWSKY STANFORD S
0
0%
$1.0322<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
HARBERT FUND ADVISORS, INC.$6.57M10.065.18M0%+$04.77
Renaissance Technologies$3.09M4.732.44M-1.78%-$55,970.810.01
The Vanguard Group$2.38M3.651.88M0%+$0<0.0001
Tang Capital Management, LLC$1.6M2.451.26M-25.88%-$558,783.660.01
BlackRock$1.21M1.85953,991+0.03%+$411.48<0.0001
Dimensional Fund Advisors$832,860.001.27655,795-10.13%-$93,836.53<0.0001
Geode Capital Management$429,203.000.66337,8560%+$0<0.0001
RBF Capital, LLC$317,956.000.49250,3590%+$00.01
Bridgeway Capital Management$288,417.000.44227,1000%+$0<0.01
State Street$195,757.000.3154,139-7.72%-$16,383.04<0.0001
Morgan Stanley$91,129.000.1471,755-5.28%-$5,080.01<0.0001
Wittenberg Investment Management Inc$86,364.000.1368,0030%+$00.03
Northern Trust$85,418.000.1367,258-40.65%-$58,506.59<0.0001
T. Rowe Price$57,000.000.0944,8000%+$0<0.0001
Kempner Capital Management Inc$32,000.000.0525,4750%+$00.02
Susquehanna International Group$30,823.000.0524,270New+$30,823.00<0.0001
32 Advisors$25,965.000.0420,4450%+$0<0.01
Assenagon Asset Management S.A.$25,112.000.0419,773-72.69%-$66,857.38<0.0001
Paradigm Financial Partners Llc$24,765.000.0419,5000%+$00.01
Raymond James Trust National Association$21,610.000.0317,0160%+$0<0.01
Shulman Demeo Asset Management$19,668.000.0315,4870%+$00.01
Sage Mountain Advisors$18,028.000.0314,1950%+$0<0.01
Xtx Topco Ltd$18,449.000.0314,527New+$18,449.00<0.0001
Charles Schwab$17,108.000.0313,4710%+$0<0.0001
Tower Research Capital$15,384.000.0212,113+46.2%+$4,861.72<0.0001
Nierenberg Investment Management Company Inc$14,675.000.0211,5550%+$00.01
Covestor Ltd$5,000.000.013,9670%+$0<0.01
Bank of America$3,033.000.012,388-23.27%-$919.55<0.0001
Benefit Financial Services Group (BFSG)$3,573.000.012,813New+$3,573.00<0.0001
JPMorgan Chase$2,328.00<0.011,8330%+$0<0.0001
Fidelity Investments$2,521.00<0.011,985+361.63%+$1,974.89<0.0001
Royal Bank of Canada$1,000.00<0.011,081-17.67%-$214.62<0.0001
Wells Fargo$1,121.00<0.01882-32.26%-$533.81<0.0001
Advisor Group Holdings Inc$1,425.00<0.011,1230%+$0<0.0001
Simplex Trading Llc$1,000.00<0.01881New+$1,000.00<0.0001
UBS$353.00<0.01278-85.17%-$2,026.58<0.0001
Sound Income Strategies$13.00<0.0110New+$13.00<0.0001
Newedge Advisors Llc$13.00<0.01100%+$0<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.